How to Test Lp(a): Practical Guide to Measurement and Monitoring

Introduction

Getting your Lp(a) measured should be straightforward. It’s a blood test. But the reality is more complicated. Different laboratories use different assays that report results in different units. Some tests are more accurate than others depending on your genetic background. And despite clear guideline recommendations, many physicians still don’t order it routinely.

This article provides practical guidance on Lp(a) testing: what to request, how to interpret the units, when retesting makes sense, and what additional tests might complement your Lp(a) measurement. Understanding the technicalities helps you advocate effectively for appropriate testing and interpret your results correctly.

Why isn’t Lp(a) part of standard lipid panels?

Standard lipid panels measure total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides because these markers were established in cardiovascular research decades before Lp(a)‘s importance was recognized. Laboratory infrastructure, clinical guidelines, and physician training all evolved around this core panel. Adding new tests to routine practice faces substantial inertia.

The evidence supporting Lp(a) measurement has accumulated more recently. The 2022 European Atherosclerosis Society consensus statement recommends measuring Lp(a) at least once in all adults to identify those at elevated risk (Kronenberg et al., 2022). The 2024 NLA update reinforces this recommendation, stating that all adults should have Lp(a) measured at least once in their lifetime.

Practically, getting Lp(a) tested requires specific ordering. It won’t appear on a standard lipid panel unless explicitly requested. Some healthcare systems include it in comprehensive lipid testing; most do not. Insurance coverage varies, though most plans cover the test with appropriate indication.

What is the difference between mass and molar assays?

Lp(a) can be reported in mass units (mg/dL) or molar units (nmol/L). These units measure different things and don’t convert cleanly. Mass units measure the total weight of Lp(a) particles, while molar units count the number of particles. The problem is that Lp(a) particles vary in size depending on apo(a) isoform.

A person with many small apo(a) isoforms and a person with few large apo(a) isoforms might have identical mass concentrations but vastly different particle numbers. Since particle number correlates better with risk than mass, molar units (nmol/L) are generally preferred (Gudbjartsson et al., 2019). The rough conversion factor of 2.5 mg/dL per nmol/L is approximate at best.

When reviewing your results, note which units your laboratory uses. The key thresholds are approximately 50 mg/dL or 125 nmol/L. Results above these levels indicate elevated Lp(a) warranting attention to overall cardiovascular risk management.

Which assay should I request?

The ideal Lp(a) assay is isoform-insensitive, meaning it provides accurate results regardless of your apo(a) size. Traditional immunoassays used antibodies that bound variably to different isoforms, producing systematic errors. Newer assays target regions of the apo(a) protein that are present in single copy, providing more consistent results (Kronenberg et al., 2022).

In practice, patients rarely get to choose their assay. Most commercial laboratories use whatever platform they’ve implemented. The best approach is to ensure you receive results from a CLIA-certified laboratory and to note which assay was used if that information is available. If your level is borderline elevated, consider retesting at a laboratory known to use isoform-insensitive methodology.

Major reference laboratories including LabCorp and Quest offer Lp(a) testing. Academic medical centers often have more sophisticated assays available through their lipid clinics. If precision matters for your clinical decision-making, consulting with a lipid specialist can help identify the most appropriate testing option.

Should I fast before Lp(a) testing?

Lp(a) levels are not significantly affected by recent food intake. Unlike triglycerides, which rise substantially after meals, Lp(a) remains relatively stable. Fasting is not required for accurate Lp(a) measurement.

This stability reflects the genetic determination of Lp(a) levels. Your liver produces Lp(a) at a rate determined primarily by your LPA gene variants, not by recent dietary intake. Day-to-day variation in Lp(a) is relatively small compared to the magnitude of differences between individuals.

When combining Lp(a) testing with a standard lipid panel (which does benefit from fasting for accurate triglyceride and calculated LDL measurement), fasting makes sense for the overall blood draw. But Lp(a) itself can be accurately measured in the non-fasting state.

How often should I retest Lp(a)?

Because Lp(a) levels are genetically determined and stable over time, routine retesting is generally unnecessary. One measurement in adulthood typically provides lifetime information. This differs fundamentally from LDL cholesterol, which responds to treatment and warrants regular monitoring.

Exceptions exist. Certain conditions can transiently affect Lp(a) levels: kidney disease tends to raise Lp(a), while acute illness can temporarily suppress it. Menopause is associated with Lp(a) increases of roughly 25%. Thyroid dysfunction affects Lp(a) in both directions. If these conditions develop, retesting may provide useful information (Tsimikas, 2017).

Once Lp(a)-lowering therapies become available, monitoring will become relevant for assessing treatment response. For now, the main reasons to retest are significant clinical state changes or to confirm an unexpectedly high or low result using a different assay methodology.

What conditions can change Lp(a) levels?

Several medical conditions influence Lp(a) concentration independently of genetics. Chronic kidney disease elevates Lp(a) through reduced clearance. Hypothyroidism increases Lp(a), while hyperthyroidism decreases it. Nephrotic syndrome is associated with substantial Lp(a) elevations.

Menopause produces clinically meaningful Lp(a) increases in many women. Estrogen has Lp(a)-lowering effects, so its decline at menopause removes this suppressive influence. Women with borderline Lp(a) levels before menopause may cross into the elevated range afterward.

Acute inflammation and illness can temporarily suppress Lp(a). Measuring Lp(a) during hospitalization or acute illness may produce falsely low results. For accurate baseline assessment, test during stable health states (Koschinsky et al., 2024).

Should I get tested after starting new therapies?

Current lipid-lowering therapies have variable effects on Lp(a). Statins may slightly increase Lp(a) in some individuals, particularly those with smaller apo(a) isoforms. PCSK9 inhibitors reduce Lp(a) by approximately 20-30%. Niacin lowers Lp(a) but failed to improve outcomes in major trials. None of these effects are large enough to routinely warrant Lp(a) retesting.

When dedicated Lp(a)-lowering therapies become available, monitoring treatment response will become standard practice. These therapies can reduce Lp(a) by 80% or more, making verification of response clinically meaningful.

For now, one baseline Lp(a) measurement suffices for most patients. If you start a PCSK9 inhibitor and want to document the modest Lp(a) reduction, retesting after several months on stable therapy is reasonable but not essential.

Should I get OxPL-apoB measured?

Oxidized phospholipids on apoB-containing lipoproteins (OxPL-apoB) reflect the inflammatory burden of Lp(a) and other atherogenic particles. Elevated OxPL-apoB is associated with faster progression of calcific aortic stenosis and coronary artery disease (Capoulade et al., 2015).

Currently, OxPL-apoB is primarily a research measure not widely available in clinical practice. If you have access through a specialized lipid clinic or research protocol, it provides additional prognostic information. For most patients, Lp(a) concentration alone provides the clinically actionable information.

As Lp(a)-lowering therapies advance, OxPL measurement may become more relevant for understanding treatment effects. These therapies reduce OxPL along with Lp(a), and OxPL reduction may contribute to clinical benefits. For now, consider it interesting research rather than routine clinical practice.

What about Lp-PLA2 and other inflammatory markers?

Lipoprotein-associated phospholipase A2 (Lp-PLA2) is an enzyme associated with vulnerable atherosclerotic plaque. It was previously marketed as a cardiovascular risk marker but has fallen out of favor after disappointing results from trials of Lp-PLA2 inhibitors. Routine testing is no longer recommended.

High-sensitivity C-reactive protein (hsCRP) remains a validated inflammatory marker that provides prognostic information independent of lipids. For patients with elevated Lp(a), hsCRP measurement can help characterize overall inflammatory burden and may influence decisions about therapies like colchicine.

Other markers like myeloperoxidase, GlycA, and various cytokines are research tools rather than clinical standards. Their measurement doesn’t currently change management decisions for most patients with elevated Lp(a).

How does Lp(a) inform imaging frequency?

Patients with elevated Lp(a) may benefit from earlier or more frequent cardiovascular imaging to detect subclinical disease. Coronary artery calcium (CAC) scoring provides information about calcified plaque burden. CT angiography reveals both calcified and non-calcified plaque, including high-risk features.

The 2019 ACC/AHA guidelines suggest that elevated Lp(a) is a “risk-enhancing factor” that may favor earlier initiation of statin therapy, particularly when combined with CAC scores above zero. For patients with elevated Lp(a) and intermediate calculated risk, imaging can help reclassify into appropriate treatment intensity.

Repeat imaging after several years can assess progression rates. If disease is progressing despite optimal medical therapy, this information may strengthen the case for aggressive intervention or clinical trial participation. Imaging decisions should be individualized based on baseline findings and risk factor control.

Should I get an echocardiogram for aortic valve monitoring?

Given Lp(a)‘s established role in calcific aortic valve stenosis, patients with elevated Lp(a) may benefit from echocardiographic screening for early valve changes. This is particularly relevant for patients over 50 or those with any cardiac symptoms.

Echocardiography can detect aortic sclerosis (thickening without obstruction) before stenosis develops. Early detection allows monitoring of progression and timely intervention when stenosis becomes hemodynamically significant. For patients with both elevated Lp(a) and detectable aortic valve disease, serial echocardiography every 1-3 years is reasonable.

The frequency of surveillance depends on baseline findings. Patients with normal valves and elevated Lp(a) might undergo echocardiography every 5 years or when symptoms develop. Those with established aortic sclerosis warrant more frequent monitoring. Your cardiologist can provide individualized recommendations based on your specific findings.

Conclusion

Lp(a) testing is simple in concept but complicated in execution. The key practical points are: request the test specifically (it won’t be on standard panels), understand which units your lab reports, expect one measurement to provide lifetime baseline information, and recognize the conditions that might warrant retesting.

Knowing your Lp(a) level provides the foundation for understanding your cardiovascular risk and making informed decisions about treatment options. It also enables appropriate cascade screening in family members who share your genetic inheritance.

The testing landscape may evolve as Lp(a)-lowering therapies approach approval. Standardized, isoform-insensitive assays will become increasingly important for monitoring treatment response. For now, the most important step is simply getting tested in the first place.